Galectin Therapeutics Inc. (GALT)

Name: Galectin Therapeutics Inc. (GALT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Galectin Therapeutics Inc. (GALT)

Stock Card

$4.20

$0.06 (1.45%)

As on 28-Aug-2026 10:39EDT

Market cap

$371 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

207.7

Div. Yield

0 %

Galectin Therapeutics (GALT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.01 High: 4.20

52 Week Range

Low: 2.03 High: 7.13

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-37.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-4
Debt to Equity

0
Book Value

$--
EPS

$-0.4
Face value

--
Shares outstanding

100,849,644

10 Years Aggregate

CFO

$-191.67 Mln

EBITDA

$-229.82 Mln

Net Profit

$-235.52 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Galectin Therapeutics (GALT)	1.0	24.3	55.6	5.5	36.5	1.6	10.0
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Galectin Therapeutics (GALT)	222.5	-22.1	46.9	-45.4	-7.6	-21.7	-16.6
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Galectin Therapeutics (GALT)	4.2	371.1	0.0	-27.8	--	--	--	207.7
Arrowhead Pharmaceuticals (ARWR)	85.4	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Ascendis Pharma A/S - ADR	248.4	16,614.0	1,054.4	755.9	5.7	--	19.4	10.1
Cytokinetics Inc (CYTK)	73.9	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	105.5	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Madrigal Pharmaceuticals (MDGL)	537.3	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	603.8	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	351.6	10,496.2	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	146.8	9,985.8	282.0	82.9	-28.6	11.4	147	11.6

Shareholding Pattern

View Details

About Galectin Therapeutics (GALT)

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which... is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Read more

President, CEO & Director

Mr. Joel Lewis
CFO, Treasurer & Corporate Secretary

Mr. Jack W. Callicutt CPA
Headquarters

Norcross, GA
Website

https://galectintherapeutics.com

FAQs for Galectin Therapeutics (GALT)

What is the current share price of Galectin Therapeutics Inc (GALT) Today?

The share price of Galectin Therapeutics Inc (GALT) is $4.20 (NASDAQ) as of 28-Aug-2026 10:39 EDT. Galectin Therapeutics Inc (GALT) has given a return of 36.46% in the last 3 years.

What is the current PB & PE ratio of Galectin Therapeutics Inc (GALT)?

Since, TTM earnings of Galectin Therapeutics Inc (GALT) is negative, P/E ratio is not available.
The P/B ratio of Galectin Therapeutics Inc (GALT) is 207.70 times as on 21-Aug-2026, a 3782 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-8.62	-2.11
2024	-1.72	-0.79
2023	-2.43	-1.66
2022	-1.73	-2.09
2021	-3.97	46.31

What is the 52 Week High and Low of Galectin Therapeutics Inc (GALT)?

The 52-week high and low of Galectin Therapeutics Inc (GALT) are Rs 7.13 and Rs 2.03 as of 28-Aug-2026.

What is the market cap of Galectin Therapeutics Inc (GALT)?

Galectin Therapeutics Inc (GALT) has a market capitalisation of $ 371 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Galectin Therapeutics Inc (GALT)?

Before investing in Galectin Therapeutics Inc (GALT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.